NASDAQ:CTMX CytomX Therapeutics (CTMX) Stock Price, News & Analysis → The CHIPS Act Motherlode (From True Market Insiders) (Ad) Free CTMX Stock Alerts $1.89 -0.11 (-5.50%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$1.85▼$1.9750-Day Range$1.59▼$5.1352-Week Range$1.04▼$5.85Volume3.54 million shsAverage Volume17.90 million shsMarket Capitalization$147.27 millionP/E Ratio9.45Dividend YieldN/APrice Target$6.53 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get CytomX Therapeutics alerts: Email Address CytomX Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.40 Rating ScoreUpside/Downside245.5% Upside$6.53 Price TargetShort InterestHealthy4.62% of Shares Sold ShortDividend StrengthN/ASustainability-0.74Upright™ Environmental ScoreNews Sentiment0.61Based on 8 Articles This WeekInsider TradingSelling Shares$73,200 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.24) to ($0.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.87 out of 5 starsMedical Sector46th out of 921 stocksPharmaceutical Preparations Industry17th out of 426 stocks 4.2 Analyst's Opinion Consensus RatingCytomX Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageCytomX Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CytomX Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.62% of the outstanding shares of CytomX Therapeutics have been sold short.Short Interest Ratio / Days to CoverCytomX Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CytomX Therapeutics has recently increased by 0.28%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCytomX Therapeutics does not currently pay a dividend.Dividend GrowthCytomX Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytomX Therapeutics has received a 74.21% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health", "Basic medical research services", and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for CytomX Therapeutics is -0.74. Previous Next 3.7 News and Social Media Coverage News SentimentCytomX Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for CytomX Therapeutics this week, compared to 2 articles on an average week.Search Interest23 people have searched for CTMX on MarketBeat in the last 30 days. MarketBeat Follows8 people have added CytomX Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CytomX Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $73,200.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of CytomX Therapeutics is held by insiders.Percentage Held by Institutions67.77% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CytomX Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.24) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CytomX Therapeutics is 9.45, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 122.97.Price to Earnings Ratio vs. SectorThe P/E ratio of CytomX Therapeutics is 9.45, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 106.31.Read more about CytomX Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. About CytomX Therapeutics Stock (NASDAQ:CTMX)CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Read More CTMX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTMX Stock News HeadlinesMay 16 at 4:15 PM | globenewswire.comCytomX Therapeutics Announces New Employment Inducement GrantsMay 13, 2024 | americanbankingnews.comCytomX Therapeutics (NASDAQ:CTMX) PT Raised to $3.59 at BMO Capital MarketsMay 13, 2024 | americanbankingnews.comHC Wainwright Reiterates "Neutral" Rating for CytomX Therapeutics (NASDAQ:CTMX)May 13, 2024 | americanbankingnews.comAnalysts Set Expectations for CytomX Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:CTMX)May 13, 2024 | americanbankingnews.comCytomX Therapeutics (NASDAQ:CTMX) Upgraded to "Outperform" by WedbushMay 12, 2024 | americanbankingnews.comCytomX Therapeutics (NASDAQ:CTMX) Rating Increased to Buy at StockNews.comMay 12, 2024 | americanbankingnews.comBrokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $6.42May 11, 2024 | wsj.comCytomX Therapeutics Inc.May 9, 2024 | finance.yahoo.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | markets.businessinsider.comCautious Hold on CytomX Therapeutics Pending Comprehensive CX-904 Drug DataMay 9, 2024 | msn.comCytomX slides after early data for Amgen-partnered cancer drugMay 9, 2024 | markets.businessinsider.comAnalysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic CancerMay 9, 2024 | investorplace.comWhy Is CytomX (CTMX) Stock Down 43% Today?May 9, 2024 | finance.yahoo.comCytomX Therapeutics Inc (CTMX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 8, 2024 | investorplace.comCTMX Stock Earnings: CytomX Therapeutics Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | globenewswire.comCytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | globenewswire.comCytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)May 7, 2024 | globenewswire.comCytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)May 7, 2024 | msn.comJefferies Upgrades CytomX Therapeutics (CTMX)May 1, 2024 | investorplace.comWhy Is CytomX (CTMX) Stock Up 180% Today?May 1, 2024 | globenewswire.comCytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024April 27, 2024 | seekingalpha.comCytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In TownApril 23, 2024 | msn.comJP Morgan Upgrades CytomX Therapeutics (CTMX)April 22, 2024 | msn.comCytomX upgraded to Neutral at J.P MorganApril 17, 2024 | finance.yahoo.comCytomX Therapeutics, Inc. (CTMX)See More Headlines Receive CTMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today5/18/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CTMX CUSIPN/A CIK1501989 Webwww.cytomx.com Phone(605) 515-3185Fax650-351-0353Employees120Year FoundedN/APrice Target and Rating Average Stock Price Target$6.53 High Stock Price Target$8.00 Low Stock Price Target$3.59 Potential Upside/Downside+245.5%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.20 Trailing P/E Ratio9.45 Forward P/E RatioN/A P/E GrowthN/ANet Income$-570,000.00 Net Margins13.87% Pretax Margin17.18% Return on Equity-30.70% Return on Assets8.10% Debt Debt-to-Equity RatioN/A Current Ratio1.16 Quick Ratio1.16 Sales & Book Value Annual Sales$101.21 million Price / Sales1.46 Cash FlowN/A Price / Cash FlowN/A Book Value($0.41) per share Price / Book-4.61Miscellaneous Outstanding Shares77,920,000Free Float72,465,000Market Cap$147.27 million OptionableOptionable Beta1.09 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Sean A. McCarthy DPHIL (Age 57)Chairman & CEO Comp: $1.03MKey CompetitorsSkye BioscienceNASDAQ:SKYECervoMedNASDAQ:CRVOI-MabNASDAQ:IMABRenovaroNASDAQ:RENBInterCureNASDAQ:INCRView All CompetitorsInsiders & InstitutionsTidal Investments LLCSold 18,006 shares on 5/17/2024Ownership: 0.370%Jacobs Levy Equity Management Inc.Sold 261,486 shares on 5/16/2024Ownership: 0.680%Vanguard Group Inc.Sold 45,569 shares on 5/10/2024Ownership: 7.129%Acadian Asset Management LLCBought 44,640 shares on 5/10/2024Ownership: 3.949%SG Americas Securities LLCBought 26,114 shares on 5/7/2024Ownership: 0.038%View All Insider TransactionsView All Institutional Transactions CTMX Stock Analysis - Frequently Asked Questions Should I buy or sell CytomX Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CTMX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTMX, but not buy additional shares or sell existing shares. View CTMX analyst ratings or view top-rated stocks. What is CytomX Therapeutics' stock price target for 2024? 5 brokers have issued 12-month price targets for CytomX Therapeutics' stock. Their CTMX share price targets range from $3.59 to $8.00. On average, they anticipate the company's share price to reach $6.53 in the next year. This suggests a possible upside of 245.5% from the stock's current price. View analysts price targets for CTMX or view top-rated stocks among Wall Street analysts. How have CTMX shares performed in 2024? CytomX Therapeutics' stock was trading at $1.55 on January 1st, 2024. Since then, CTMX shares have increased by 21.9% and is now trading at $1.89. View the best growth stocks for 2024 here. When is CytomX Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our CTMX earnings forecast. How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced its earnings results on Monday, March, 11th. The biotechnology company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.02 by $0.01. The biotechnology company earned $26.61 million during the quarter, compared to analyst estimates of $23.36 million. CytomX Therapeutics had a net margin of 13.87% and a negative trailing twelve-month return on equity of 30.70%. What ETF holds CytomX Therapeutics' stock? Formidable ETF holds 282,099 shares of CTMX stock, representing 4.48% of its portfolio. What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO? 12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend. What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX). Who are CytomX Therapeutics' major shareholders? CytomX Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.13%), Acadian Asset Management LLC (3.95%), Jacobs Levy Equity Management Inc. (0.68%), Tidal Investments LLC (0.37%), Congress Park Capital LLC (0.35%) and Susquehanna Fundamental Investments LLC (0.08%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Christopher Ogden, Elaine V Jones, Jeffrey B Landau, Lloyd A Rowland, Marcia Belvin and Sean A Mccarthy. View institutional ownership trends. How do I buy shares of CytomX Therapeutics? Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CTMX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.